Noticias de Eulerpool Satsuma Pharmaceuticals

Satsuma Pharmaceuticals Eulerpool-AFX

Satsuma Pharmaceuticals Noticias de Acciones

Satsuma Pharmaceuticals es observado por muchos periodistas e inversores en todo el mundo. Aquí recopilamos las noticias más recientes de Satsuma Pharmaceuticals.

• 17 de julio ·

  SeekingAlpha
  Leaven Partners Second Quarter 2023 Letter To Partners
• 9 de junio ·

  Benzinga
  Satsuma Pharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
• 18 de mayo ·

  Yahoo
  Satsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of Migraine
• 18 de mayo ·

  Seeking Alpha
  Satsuma migraine therapy accepted for FDA review
• 18 de mayo ·

  Thefly.com
  Satsuma: FDA accepts NDA for STS101 for acute migraine treatment
• 15 de mayo ·

  TipRanks
  JonesTrading Sticks to Its Hold Rating for Satsuma Pharmaceuticals (STSA)
• 21 de abril ·

  Yahoo
  Satsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual Meeting
• 21 de abril ·

  Thefly.com
  Satsuma Pharmaceuticals announces three abstracts accepted at AAN meeting
• 19 de abril ·

  Thefly.com
  Biotech Alert: Searches spiking for these stocks today
• 19 de abril ·

  Fintel
  HC Wainwright & Co. Downgrades Satsuma Pharmaceuticals (STSA)